CEFALY Technology

CEFALY Technology manufactures FDA-cleared wearable neuromodulation devices for the acute treatment and prevention of migraine headaches. The CEFALY device is a transcutaneous electrical nerve stimulation (TENS) system that targets supraorbital nerve pathways to reduce migraine pain and frequency without pharmaceutical intervention. The company positions its products as drug-free alternatives for migraine management, with clinical evidence demonstrating reduction in migraine days and decreased reliance on migraine medications. The device operates through two treatment modes: an ACUTE program for rapid pain relief during active migraine attacks, and a PREVENT program (20-minute daily protocol) for long-term migraine frequency reduction. CEFALY offers connected device options integrated with the CeCe Migraine Management mobile application (iOS and Android), enabling patients to track treatments, identify migraine patterns, and optimize therapy protocols. The product has been in clinical use since 2008 and is relied upon by tens of thousands of patients. The company emphasizes safety and tolerability, with no serious adverse effects reported and a 90-day money-back guarantee. Distribution is direct-to-consumer via the company website with flexible payment options including Affirm financing, PayPal Credit, and HSA/FSA eligibility. CEFALY maintains regulatory clearance through FDA approval and positions its neuromodulation technology as addressing medication overuse headache (MOH) concerns and cognitive side effects associated with traditional migraine pharmaceuticals.